Organization
Drugmakers renew concerns over UK’s attractiveness for investment
Investments, UK, UK ‘s, concerns, Industry, attractiveness
Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics
OBT, therapeutic autologous dendritic cells, Roche (company), Partnership, Oxford BioTherapeutics, Antibody-Drug Conjugates, biobucks, New
Sutro discards CEO, 50% of staff, sole clinical-stage ADC and manufacturing site to save cash
Sutro, therapeutic autologous dendritic cells, Changing, CEO, Cash
Federal Circuit ruling allows Amgen’s Eylea biosimilar to stay on the market
Market, Amgen ‘s, Pavblu, Amgen, Eylea biosimilar, Regeneron, Federal Circuit, court, Eylea
Roche expands obesity pipeline, paying Zealand Pharma $1.65B upfront to codevelop amylin asset
This deal represents a major expansion of Roche’s obesity drug pipeline and a significant partnership in the competitive weight loss medication market.
Daiichi turns to Nosis for AI-designed RNA delivery tech
Nosis, Daiichi, RNA, Sankyo, Partnership, Biosciences, Cells, Chronic disease
BMS snaps up Abecma partner 2seventy bio in $286M all-cash deal
Burning Mouth Syndrome, Abecma, BMS, Abecma
US judge blocks Trump administration from cutting NIH grants amid ongoing litigation
United States National Institutes of Health, Judge, injunction, implementing